GlassScriptPhysician profile
Steven M Lieberman
NPI 1891762761
$5,051.19
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $160 · 2021: $515 · 2022: $783 · 2023: $1,109 · 2024: $773 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $786.27 | 2019-2025 | |
| Pfizer INC. | $714.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $525.04 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $485.46 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $417.49 | 2019-2023 | Xarelto |
| Amgen INC. | $390.33 | 2019-2024 | Repatha |
| Abbott Laboratories | $282.22 | 2022-2025 | Cardiomems, Ensite Precision, Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $239.60 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $234.37 | 2020-2025 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $193.44 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.50 | 2019-2025 | Lifevest |
| Medtronic, INC. | $146.58 | 2021-2022 | |
| Elutia, INC. | $71.26 | 2022-2023 | |
| Novo Nordisk INC | $45.88 | 2023 | Ozempic, Rybelsus |
| Heartflow, INC. | $37.99 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $35.99 | 2019 | |
| Abiomed | $34.49 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $33.83 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $30.72 | 2021 | |
| Chiesi USA, INC. | $30.62 | 2022-2023 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $28.73 | 2023 | Watchman Access System |
| Nuwellis, INC. | $26.77 | 2023 | Aquadex Smartflow Console |
| Alnylam Pharmaceuticals INC. | $17.95 | 2025 | Amvuttra |
| Tactile Systems Technology INC | $17.93 | 2023 | Flexitouch Plus, Entre Plus |
| Surmodics, INC. | $17.79 | 2022 | |
| Itamar Medical INC | $16.34 | 2023 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.